Determination and pharmacokinetic profile of liposomal foscarnet in rabbit ocular tissues after intravitreal administration

Experimental Eye Research

Volumn 88, Issue 3, 2009, Pages 528-534

  Claro, Carmen ^a   Ruiz, Rosa ^b   Cordero, Elisa ^b   Pastor, Ma Teresa ^b   López Cortés, Luis Fernando ^b   Jiménez Castellanos, Ma Rosa ^a   Lucero, Ma Jesús ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

foscarnet; intravitreal administration; liposomes; ocular pharmacokinetics; retina; vitreous humor

Indexed keywords

FOSCARNET; FOSCARNET SODIUM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUTION; ENCAPSULATION; EVAPORATION; LIPOSOMAL DELIVERY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; VITREOUS BODY;

ANIMALS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EYE; FOSCARNET; LIPOSOMES; MODELS, BIOLOGICAL; RABBITS; RETINA; VITREOUS BODY;

EID: 61549129311     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.11.015     Document Type: Article

References (35)

1. Betageri G.V., Jenkins S.A., and Parsons D.L. Liposome Drug Delivery Systems (1993), Technomic Publishing, Lancaster
2. Biron K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71 (2006) 154-163
3. Bochot A., Couvreur P., and Fatal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retinal Eye Res. 19 (2000) 131-147
4. Cheng L., Hostler K., Chaidbawangul S., Gadner M., Beadle J., Keefe K., Bergeron-Lynn G., Severson G., Soules K., Mueller A., and Freeman W. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest. Ophthalmol. Vis. Sci. 41 (2000) 1523-1532
5. Díaz-Llopis M., Martos M.J., España E., Cervera M., Vila A.O., Navea A., Molina F.J., and Romero F.J. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Doc. Ophthalmol. 82 (1992) 297-305
6. Doménech J., and Lauroba J. Farmacocinética no compartimental. In: Doménech J., Martínez J., and Plá J.M. (Eds). Biofarmacia y Farmacocinética: Farmacocinética vol. I (1997), Síntesis, Madrid 391-409
7. Dusserre N., Lessard C., Paquette N., Perron S., Poulin L., Tremblay M., Beauchamp D., Désormeaux A., and Bergeron M. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. A.I.D.S. 9 (1995) 833-841
8. Eldem T., Arican-Cellat N., Agabeyoglu I., Akova M., and Kansu E. Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. Int. J. Pharm. 213 (2001) 153-161
9. Engstrom R.E., and Holland G.N. Local therapy for cytomegalovirus retinopathy. Am. Soc. Microbiol. 120 (1995) 376-385
10. García J., Lucero M.J., León M.J., and López L.F. Estudio del Foscarnet como alternativa al tratamiento antiherpético. Cienc. Pharm. 5 (1997) 209-218
11. Garré B., van der Meulen K., Nugent J., Neyts J., Croubels S., De Backer P., and Nauwynck H. Vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet. Microbiol. 122 (2007) 43-51
12. Grohganz H., Tho I., and Brandl M. Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix. Eur. J. Pharm. Biopharm. 59 (2005) 439-448
13. Helgrand E., Eriksson B., and Johansson N.G. Trisodium phosphonoformate, a new antiviral compound. Science 201 (1978) 819-821
14. Herrero-Vanrell R., and Refojo M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Del. Rev. 52 (2001) 5-16
15. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointment. J. Soc. Cosmet. Chem. 11 (1960) 85-90
16. Higuchi T. Rate of release of medicaments from ointment bases containing drug in suspension. J. Pharm. Sci. 50 (1961) 874-875
17. Higuchi T. Mechanism of sustained-action medication. J. Pharm. Sci. 52 (1963) 1145-1149
18. Jacobson M.A., Polsky B., and Causey D. Pharmacodynamic relationship of pharmacokinetics parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. Am. Soc. Microbiol. 5 (1994) 1190-1199
19. Kim H., Csaky K.G., Chan C., Bungay P.M., Lutz R.J., Dedrick R.L., Yuan P., Rosenberg J., Grillo-López A.J., Wilson W.H., and Robinson M.R. The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. 82 (2006) 760-766
20. Liu K.R., Peyman G.A., and Khoobehi B. Efficacy of liposome-bound amphotericin for the treatment of experimental fungal endophthalmitis in rabbits. Invest. Ophthalmol. Vis. Sci. 30 (1989) 1527-1534
21. Long M., Bidanset D., Williams S., Kushner N., and Kern E. Determination of antiviral efficacy against lymphotropic herpesvirus utilizing flow cytometry. Antivir. Res. 58 (2003) 149-157
22. López-Cortés L.F., Ruiz R., Lucero M.J., Cordero E., Pastor M.T., and Márquez J. Intravitreal, retinal and central nervous system foscarnet concentration after rapid intravenous administration to rabbits. Antimicrob. Agents Chemother. 44 (2000) 756-759
23. López-Cortés L.F., Pastor M.T., Ruiz R., Cordero E., Uceda A., Claro C.M., and Lucero M.J. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1024-1128
24. Martínez-Sancho C., Herrero-Vanrell R., and Negro S. Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release. Int. J. Pharm. 326 (2006) 100-106
25. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 40 (1989) 213-285
26. Omar R.F., Dusserre N., Désormeauz A., Poulin L., Tremblay M., Beauchamp D., and Dergeron M.G. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob. Agents Chemother. 39 (1995) 1973-1978
27. Papagiannaros A., Hatziantoniou S., Dimas K., Papaioannou G.T., and Demetzos C. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC) physicochemical characterization and cytotoxic activity against human cancer cell lines. Biomed. Pharmacother. 60 (2005) 36-42
28. Peterson L.W., Kashemirov B.A., Saejueng K., Breitenbach J., Borysco K., Drach J.C., Kim J.S., Kijek P., Mitchell S., Hilfinger J.M., and McKenna C.E. Novel synthetic approaches to cidofovir and foscarnet prodrugs. Antivir. Res. 74 (2007) A74-A114
29. Pettersson K.J., and Nordgren T. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography. J. Chromatogr. Biomed. 488 (1989) 447-455
30. Peyman G.A., and Ganiban J. Delivery systems for intraocular routes. Adv. Drug Del. Rev. 16 (1995) 107-123
31. Schoenwald R.D. Pharmacokinetics in Ocular Drug Delivery. Biopharmaceutics of Oocular Drug Delivery (1993), CRC Press, Boca Raton
32. Tojo K., Nakagawa K., Morita Y., and Ohtori A. A pharmacokinetic model of intravitreal delivery of ganciclovir. Eur. J. Pharm. Biopharm. 47 (1999) 99-104
33. Wang T., Deng Y., Geng Y., Gao Z., Zou J., and Wang Z. Preparation of submicron unilamellar liposomes by freeze-drying double emulsions. Biochim. Biophys. Acta 1758 (2006) 222-231
34. Worabul N., and Robison J.R. Ocular pharmacokinetics/pharmadynamics. Eur. J. Pharm. Biopharm. 44 (1977) 71-83
35. Wu X., Itoh N., Taniguchi T., Nakanishi T., and Tanaka K. Requirement of calcium and phosphate ions in expression of sodium-dependent vitamin C transporter 2 and osteopontin in MC3T3-E1 osteoblastic cells. Biochim. Biophys. Acta-Mol. Cel. Res. 1641 (2003) 65-70